Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human adult muscle nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel located at the postsynaptic membrane of the neuromuscular junction. It is composed of two alpha-1, one beta-1, one delta, and one epsilon subunit, a configuration that distinguishes it from the fetal form which contains a gamma subunit (StatPearls, 2023). The receptor's primary biological role is to mediate fast excitatory transmission by opening a cation-selective pore in response to the binding of acetylcholine, which leads to muscle fiber depolarization and subsequent contraction (PubMed, PMC2679882). In clinical medicine, this receptor is a major therapeutic target for neuromuscular blocking agents used during surgery to facilitate intubation and provide muscle relaxation (NIH, 2022). It is also the primary target of autoimmune attack in Myasthenia Gravis, where antibodies against the receptor cause its internalisation and destruction, resulting in severe muscle weakness (UniProt, P02708). Furthermore, various congenital myasthenic syndromes arise from genetic mutations in the subunits of this receptor, affecting its expression or kinetic properties (PubMed, 25533363).
Drugs targeting this receptor primarily function through two distinct mechanisms: competitive antagonism, where non-depolarizing agents bind to the receptor to prevent acetylcholine from initiating an action potential, and depolarizing agonism, where agents like succinylcholine cause persistent activation leading to receptor desensitization and muscle relaxation.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Muscle nicotinic acetylcholine receptor (adult) (nAChR) (nAChR).